Kitamura, Shigekazu http://orcid.org/0000-0001-7162-4265
Takeshima, Takao
Yui, Daishi
da Silva Lima, Gabriel Paiva
Koukakis, Reija
Peng, Cheng
Yoshida, Ryuji
Numachi, Yotaro
Hasebe, Miki
Funding for this research was provided by:
Amgen
Article History
Received: 7 June 2023
Accepted: 16 August 2023
First Online: 12 September 2023
Declarations
:
: Shigekazu Kitamura and Takao Takeshima have nothing to disclose that could be construed as a conflict of interest. Reija Koukakis, Daishi Yui, Gabriel Paiva da Silva Lima, Cheng Peng, Ryuji Yoshida, Yotari Numachi, and Miki Hasebe are/were employees of Amgen. Reija Koukakis, Daishi Yui, Gabriel Paiva da Silva Lima, and Miki Hasebe disclose ownership of Amgen stock. Ryuji Yoshida is now affiliated with UCB Japan (Tokyo, Japan) and Yotaro Numachi is affiliated with Yu Mental Clinic (Tokyo, Japan).
: This post-hoc analysis study involved human patients who provided informed consent for participation in the study that was approved by ethics committees and institutional review boards listed in the Supplementary Material. Oversight and conduct of the study were done in accordance with the ethical guidelines of the Declaration of Helsinki, Good Clinical Practice guidelines of the International Council for Harmonisation, and related regulations in Japan.